Table 2.
Comparison of outcomes in the dapagliflozin and prevention of adverse outcomes in heart failure trial (DAPA‐HF) and empagliflozin outcome trial in patients with chronic heart failure and a reduced ejection fraction (EMPEROR‐Reduced).
| DAPA‐HF | EMPEROR‐Reduced | |||||
|---|---|---|---|---|---|---|
| Dapagliflozin | Placebo | HR (95% CI) | Empagliflozin | Placebo | HR (95% CI) | |
| Primary composite outcome, n (%) | 386 (16.3) | 502 (21.2) | 0.74 (0.65–0.85) | 361 (19.4) | 462 (24.7) | 0.75 (0.65–0.86) |
| Type 2 diabetes at baseline, n (%) | ||||||
| Yes | 215 (20.0) | 271 (25.5) | 0.75 (0.63–0.90)† | 200 (21.6) | 265 (28.5) | 0.72 (0.60–0.87) |
| No | 171 (13.2) | 231 (17.7) | 0.73 (0.60–0.88)† | 161 (17.2) | 197 (21.0) | 0.78 (0.64–0.97) |
| Patients without type 2 diabetes at baseline, n (%) | ||||||
| Hemoglobin A1c <5.7% | 53 (12.1) | 71 (16.9) | 0.67 (0.47–0.96)† | NA | NA | NA |
| Hemoglobin A1c 5.7–6.4% | 118 (13.7) | 160 (18.0) | 0.74 (0.59–0.94)† | NA | NA | NA |
| Change of laboratory and other measures from baseline‡ | ||||||
| A1c (%) | −0.21 ± 1.14* | 0.04 ± 1.29 | −0.28 ± 0.03* | −0.12 ± 0.03 | ||
| Weight (kg) | −0.88 ± 3.86* | 0.10 ± 4.09 | −0.73 ± 0.13* | 0.08 ± 0.13 | ||
| Systolic blood pressure (mmHg) | −1.92 ± 14.92* | −0.38 ± 15.27 | −2.4 ± 0.4 | −1.7 ± 0.4 | ||
The primary composite outcome in dapagliflozin and prevention of adverse outcomes in heart failure trial (DAPA‐HF) trial included hospitalization for heart failure, an urgent visit for heart failure and cardiovascular death. The primary composite outcome in empagliflozin outcome trial in patients with chronic heart failure and a reduced ejection fraction (EMPEROR‐Reduced) included cardiovascular death and hospitalization for worsening heart failure. *P < 0.05 versus placebo. † P‐values for interaction in DAPA‐HF trial were 0.80 for patients with and without type 2 diabetes at baseline and 0.72 for patients with A1c <5.7% and hemoglobin A1c (A1c) 5.7–6.4%. P‐value for interaction in patients with and without diabetes was not reported in EMPEROR‐Reduced. ‡In DAPA‐HF, changes from baseline to 8 months were shown. In EMPEROR‐Reduced, changes from baseline to 52 weeks are shown. NA, not available.